Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
iTeos Therapeutics (ITOS)
NASDAQ:ITOS
iTeos Therapeutics (ITOS) Stock Price & Analysis
142 Followers
ITOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.20 - $18.24
Previous Close$10.33
Volume209.16K
Average Volume (3M)267.70K
Market Cap
$370.26M
Enterprise Value-$155.60M
Total Cash (Recent Filing)$531.92M
Total Debt (Recent Filing)$6.06M
Price to Earnings (P/E)-3.3
Beta0.89
Next Earnings
May 09, 2024EPS Estimate
-$0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.15
Shares Outstanding35,843,131
10 Day Avg. Volume164,733
30 Day Avg. Volume267,703
Standard Deviation0.19
R-Squared0.10
Alpha-0.00608
Financial Highlights & Ratios
Price to Book (P/B)0.69
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-453.64
Enterprise Value/Gross Profit-12.35
Enterprise Value/Ebitda1.44
Forecast
1Y Price Target
$31.25Price Target Upside202.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
iTeos Therapeutics News
Ownership Overview
51.16% Insiders
13.79% Mutual Funds
9.77% Other Institutional Investors
25.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ITOS FAQ
What was iTeos Therapeutics’s price range in the past 12 months?
iTeos Therapeutics lowest stock price was $8.20 and its highest was $18.24 in the past 12 months.
What is iTeos Therapeutics’s market cap?
Currently, no data Available
When is iTeos Therapeutics’s upcoming earnings report date?
iTeos Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 20 days.
How were iTeos Therapeutics’s earnings last quarter?
iTeos Therapeutics released its earnings results on Mar 06, 2024. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$1.033 by $0.183.
Is iTeos Therapeutics overvalued?
According to Wall Street analysts iTeos Therapeutics’s price is currently Undervalued.
Does iTeos Therapeutics pay dividends?
iTeos Therapeutics does not currently pay dividends.
What is iTeos Therapeutics’s EPS estimate?
iTeos Therapeutics’s EPS estimate is -$0.98.
How many shares outstanding does iTeos Therapeutics have?
iTeos Therapeutics has 35,843,132 shares outstanding.
What happened to iTeos Therapeutics’s price movement after its last earnings report?
iTeos Therapeutics reported an EPS of -$0.85 in its last earnings report, beating expectations of -$1.033. Following the earnings report the stock price went up 7.804%.
Which hedge fund is a major shareholder of iTeos Therapeutics?
Among the largest hedge funds holding iTeos Therapeutics’s share is RA Capital Management. It holds iTeos Therapeutics’s shares valued at 48M.
---
iTeos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.25 (202.52% Upside)
$31.25 (202.52% Upside)
Blogger Sentiment
Bullish
ITOS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 136.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.49%
12-Months-Change
Fundamentals
Return on Equity
-18.19%
Trailing 12-Months
Asset Growth
-11.58%
Trailing 12-Months
Company Description
iTeos Therapeutics
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
---
ITOS Stock 12 Months Forecast
Average Price Target
$31.25
▲(202.52% Upside)
Technical Analysis
Best Analysts Covering ITOS
1 Year
1 Year Success Rate
3/13 ratings generated profit
1 Year Average Return
-15.67%
reiterated a buy rating last month
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of -15.67% per trade.
---